transdermal glp-1 receptor agonist patch clinical trial Research Summaries accompanying Original Articles in the April 23, 2026, issue of NEJM: β£ β£ ππ‘π«ππ ππ§ππ’π‘π²π©ππ«πππ§π¬π’π―ππ¬ π’π§ π ππ’π§π π₯π ππ’π₯π₯ πππππ« ππ§ππ«ππππ«πππ«ππ₯ πππ¦π¨π«π«π‘ππ π (πππππππ) β£ Among Oral Treatment of Obesity by
Description
Additionally, a multi-country study found substantial demand for GLP-1 medications among people without medical indications, highlighting the evolving landscape of body image and obesity treatment (Jensen et al., 2025)
This study supports the ongoing monitoring of tirzepatide to ensure its safe use in clinical settings [17]
Development of a novel drug delivery system to deliver drugs directly to the colonic mucosa, resulting in improved efficacy and reduced systemic exposure for the treatment of ulcerative colitis
[DOI] [PMC free article] [PubMed] [Google Scholar] 62.Lee S.-Y., Wu S.-T., Du C.-X., Ku H.-C
Hormonal changes and pregnancy-related risks make womens heart health especially complex
On the other hand, GLP-1 RAs were found to alter the gastric/small bowel motility and appetite/satiation via central or parasympathetic (vagal-mediated) pathways, leading to an increased incidence of retained gastric contents (RGCs) with the associated aspiration risk during the perioperative period [6,7,8]
